JP2023517660A5 - - Google Patents

Info

Publication number
JP2023517660A5
JP2023517660A5 JP2022554748A JP2022554748A JP2023517660A5 JP 2023517660 A5 JP2023517660 A5 JP 2023517660A5 JP 2022554748 A JP2022554748 A JP 2022554748A JP 2022554748 A JP2022554748 A JP 2022554748A JP 2023517660 A5 JP2023517660 A5 JP 2023517660A5
Authority
JP
Japan
Prior art keywords
sequence number
constant region
fragment
isolated protein
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517660A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/052121 external-priority patent/WO2021181366A1/en
Publication of JP2023517660A publication Critical patent/JP2023517660A/ja
Publication of JP2023517660A5 publication Critical patent/JP2023517660A5/ja
Pending legal-status Critical Current

Links

JP2022554748A 2020-03-13 2021-03-15 シグレック３／ｃｄ３３に結合させるための材料及び方法 Pending JP2023517660A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062989071P 2020-03-13 2020-03-13
US202062989187P 2020-03-13 2020-03-13
US202062989120P 2020-03-13 2020-03-13
US202062989230P 2020-03-13 2020-03-13
US202062989093P 2020-03-13 2020-03-13
US62/989,071 2020-03-13
US62/989,093 2020-03-13
US62/989,230 2020-03-13
US62/989,120 2020-03-13
US62/989,187 2020-03-13
PCT/IB2021/052121 WO2021181366A1 (en) 2020-03-13 2021-03-15 Materials and methods for binding siglec-3/cd33

Publications (2)

Publication Number Publication Date
JP2023517660A JP2023517660A (ja) 2023-04-26
JP2023517660A5 true JP2023517660A5 (enExample) 2024-03-19

Family

ID=75108687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554748A Pending JP2023517660A (ja) 2020-03-13 2021-03-15 シグレック３／ｃｄ３３に結合させるための材料及び方法

Country Status (20)

Country Link
US (4) US20240293453A1 (enExample)
EP (4) EP4233894A3 (enExample)
JP (1) JP2023517660A (enExample)
KR (4) KR20230051617A (enExample)
CN (1) CN115768482A (enExample)
AR (3) AR129169A2 (enExample)
AU (4) AU2021235564A1 (enExample)
BR (1) BR112022018176A2 (enExample)
CA (1) CA3171113A1 (enExample)
CL (4) CL2022002488A1 (enExample)
CO (1) CO2022013823A2 (enExample)
EC (1) ECSP22071278A (enExample)
IL (4) IL302347A (enExample)
JO (1) JOP20220220A1 (enExample)
MX (1) MX2022011320A (enExample)
PE (4) PE20240019A1 (enExample)
PH (1) PH12022552370A1 (enExample)
TW (1) TW202144418A (enExample)
UY (4) UY40279A (enExample)
WO (1) WO2021181366A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021225870A1 (en) * 2020-02-27 2022-10-20 Janssen Biotech, Inc. Materials and methods for modulating an immune response
CA3229822A1 (en) * 2021-09-13 2023-03-16 Patrick John DOONAN Cd33 x v?2 multispecific antibodies for the treatment of cancer
CA3238172A1 (en) * 2021-11-12 2023-05-19 Janssen Biotech, Inc. Materials and methods for improved expansion and uses of immune cells
WO2025120583A2 (en) * 2023-12-08 2025-06-12 Janssen Biotech, Inc. CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
WO2026006719A1 (en) * 2024-06-28 2026-01-02 IN8bio, Inc. Multifunctional molecules and methods of treatment

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
MX2009006638A (es) 2006-12-18 2009-07-02 Arigen Pharmaceuticals Inc Agente para erradicar helicobacter pylori que tiene actividad inhibidora sobre la secrecion de acido gastrico.
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
MX366910B (es) 2013-03-15 2019-07-30 Janssen Biotech Inc Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
MA40609B1 (fr) 2014-09-05 2020-05-29 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
HK1252675A1 (zh) * 2015-06-12 2019-05-31 Alector Llc 抗cd33抗体及其使用方法
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
WO2019060695A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. CHIMERIC POLYPEPTIDES AND USES THEREOF
BR112020012099A2 (pt) 2017-12-18 2020-11-17 Janssen Biotech, Inc. radiomarcação de polipeptídeos
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها

Similar Documents

Publication Publication Date Title
JP2023517660A5 (enExample)
US11202828B2 (en) Therapeutic SIRP-α antibodies
EP3180363B1 (en) Sirp-alpha immunoglobulin fusion proteins
CN108976300B (zh) Pd-1结合分子和其使用方法
US20210214440A1 (en) Materials and methods for in vivo biological targeting
CA3020864A1 (en) Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
TW201702265A (zh) 結合lag-3的分子和其使用方法
TW202208429A (zh) 用於治療多發性骨髓瘤之方法
TWI814715B (zh) Ａｄａｍ９結合分子及使用其的方法
US20230279108A1 (en) Therapeutic sirp-alpha antibodies
JP2021505637A (ja) 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
US20240336686A1 (en) Novel multi-specific molecules
JP2025508692A (ja) 免疫複合体及びその使用
WO2025085857A1 (en) Sirp antibodies for treatment of cancer
EP4551605A2 (en) Methods and compositions for treating autoimmune, allergic and inflammatory diseases
WO2023028715A1 (en) Fc variant with high thermal stability and attenuated effector function
KR20240052030A (ko) 높은 열 안정성 및 감쇠된 효과기 기능을 갖는 fc 변이체
WO2024102948A1 (en) Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
EA052211B1 (ru) ВАРИАНТ Fc С ВЫСОКОЙ ТЕРМОСТАБИЛЬНОСТЬЮ И ОСЛАБЛЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
JP2024508764A5 (enExample)
HK1237789A1 (en) Sirp-alpha immunoglobulin fusion proteins
HK1237789B (en) Sirp-alpha immunoglobulin fusion proteins